Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01801293 | A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806 | PHASE1 | COMPLETED | 8 | — | — | Mar 1, 2013 | Apr 1, 2013 | Jun 10, 2013 | 1 | United States |
The primary outcome measure of this study is the urine and fecal recovery of total \[14C\]-radioactivity.
| Arm | Type | Description |
|---|---|---|
| Intervention Arm | EXPERIMENTAL | One-time single dose of 50 mg radiolabeled GS-5806 administered orally in 3 capsules in the morning. |
| Name | Type | Description |
|---|---|---|
| GS-5806 | DRUG | - |
Inclusion Criteria: * Have a calculated body mass index (BMI) from 19 to 30 kg/m2 at study screening. * In the opinion of the Investigator, subjects must be in good health based upon medical history, physical examination (including vital signs), and screening and baseline laboratory evaluations (he...